Literature DB >> 28509137

Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Tamami Fujiki1, Suguru Hirasawa2, Seishi Watanabe2, Shunsuke Iwamoto2, Ryoichi Ando2.   

Abstract

Successful use of tocilizumab (TCZ) to treat TAFRO syndrome has recently been reported. In those cases, TCZ was used with steroid. We present herein the case of a 59-year-old man with very severe TAFRO syndrome who was successfully treated using TCZ without steroid. He showed rapidly progressive anasarca, acute renal failure and very severe thrombocytopenia. We initially used steroid, but its efficacy was limited. Moreover, steroid use had to be stopped as soon as possible, because hemorrhagic shock developed due to severe duodenal ulcer. After overcoming infections (about 40 days after stopping steroid), administration of TCZ was started and the patient was discharged in clinical remission.

Entities:  

Keywords:  Renal failure; Steroid; TAFRO syndrome; Tocilizumab

Year:  2017        PMID: 28509137      PMCID: PMC5438817          DOI: 10.1007/s13730-017-0253-6

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  16 in total

1.  Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy.

Authors:  Noriko Iwaki; Yasuharu Sato; Katsuyoshi Takata; Eisei Kondo; Kyotaro Ohno; Mai Takeuchi; Yorihisa Orita; Shinji Nakao; Tadashi Yoshino
Journal:  J Clin Exp Hematop       Date:  2013

2.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

3.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.

Authors:  Shiho Fujiwara; Hiromi Mochinaga; Hirotomo Nakata; Koichi Ohshima; Masanori Matsumoto; Mitsuhiro Uchiba; Yoshiki Mikami; Hiroyuki Hata; Yutaka Okuno; Hiroaki Mitsuya; Kisato Nosaka
Journal:  Int J Hematol       Date:  2016-03-15       Impact factor: 2.490

Review 4.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

5.  Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.

Authors:  Yoshinobu Konishi; Satoshi Takahashi; Katsuyuki Nishi; Taro Sakamaki; Sachiko Mitani; Hitomi Kaneko; Chisato Mizutani; Naoya Ukyo; Hirokazu Hirata; Mitsuru Tsudo
Journal:  Tohoku J Exp Med       Date:  2015-08       Impact factor: 1.848

6.  FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin.

Authors:  S J O'Keefe; J Tamura; R L Kincaid; M J Tocci; E A O'Neill
Journal:  Nature       Date:  1992-06-25       Impact factor: 49.962

7.  Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.

Authors:  Hiroshi Kawabata; Shin-ichi Kotani; Yumi Matsumura; Tadakazu Kondo; Tatsuya Katsurada; Hironori Haga; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Intern Med       Date:  2013-07-01       Impact factor: 1.271

8.  Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.

Authors:  Shotaro Tatekawa; Koji Umemura; Ryuichi Fukuyama; Akio Kohno; Masafumi Taniwaki; Junya Kuroda; Yoshihisa Morishita
Journal:  Clin Case Rep       Date:  2015-04-22

9.  Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Authors:  Silvia Tedesco; Laura Postacchini; Lucia Manfredi; Gaia Goteri; Michele M Luchetti; Antonella Festa; Armando Gabrielli; Giovanni Pomponio
Journal:  Exp Hematol Oncol       Date:  2015-01-14

10.  The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.

Authors:  Ikuko Kubokawa; Akihiro Yachie; Akira Hayakawa; Satoshi Hirase; Nobuyuki Yamamoto; Takeshi Mori; Tomoko Yanai; Yasuhiro Takeshima; Eiryu Kyo; Goichi Kageyama; Hiroshi Nagai; Keiichiro Uehara; Masaru Kojima; Kazumoto Iijima
Journal:  BMC Pediatr       Date:  2014-06-02       Impact factor: 2.125

View more
  5 in total

1.  Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

Authors:  Toshikazu Ozeki; Masashi Tsuji; Junichiro Yamamoto; Chisato Shigematsu; Shoichi Maruyama
Journal:  CEN Case Rep       Date:  2018-05-15

2.  A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification despite hypocalcemia: a case report.

Authors:  Shogo Minomo; Yu Fujiwara; Shota Sakashita; Akito Takamura; Kaoru Nagata
Journal:  J Med Case Rep       Date:  2021-01-06

3.  International definition of iMCD-TAFRO: future perspectives.

Authors:  Yoshito Nishimura; Midori Filiz Nishimura; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2022-04-27

4.  Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage.

Authors:  Yuhei Noda; Yosuke Saka; Akihisa Kato; Tetsushi Mimura; Tomohiko Naruse
Journal:  Clin Nephrol Case Stud       Date:  2018-06-22

5.  Severe refractory TAFRO syndrome requiring continuous renal replacement therapy complicated with Trichosporon asahii infection in the lungs and myocardial infarction: an autopsy case report and literature review.

Authors:  Arata Hibi; Ken Mizuguchi; Akiko Yoneyama; Takahisa Kasugai; Keisuke Kamiya; Keisuke Kamiya; Chiharu Ito; Satoru Kominato; Toshiyuki Miura; Katsushi Koyama
Journal:  Ren Replace Ther       Date:  2018-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.